Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 699

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 6
Chunk 699
---
 expect to continue to incur significant
expenses and increasing operating losses for the foreseeable future, which may fluctuate significantly from quarter-to-quarter and year-to-year.
We anticipate that our expenses will increase substantially as we:

    ●
    continue research and development, including preclinical and clinical development of our existing product candidates;

    ●
    potentially seek regulatory approval for our product candidates;

61

    ●
    seek to discover and develop additional product candidates;

    ●
    establish a commercialization infrastructure and scale up our manufacturing and distribution capabilities to commercialize any of our product candidates for which we may obtain regulatory approval;

    ●
    seek to comply with regulatory standards and laws;

    ●
    maintain, leverage and expand our intellectual property portfolio;

    ●
    hire clinical, manufacturing, scientific and other personnel to support our product candidate’s development and future commercialization efforts;

    ●
    add operational, financial and management information systems and personnel; and

    ●
    incur additional legal, accounting and other expenses in operating as a public company.

General and Administrative Expenses 

General and administrative
expenses consist principally of payroll and personnel expenses, including stock-based compensation; professional fees for legal, consulting,
accounting and tax services; insurance, overhead, including rent and utilities; and other general operating expenses not otherwise classified
as research and development expenses.

Other income, net

Other expense consists primarily
of interest expense incurred on debt, partially offset by interest income from a money market investment.

Critical Accounting Estimates

This management’s discussion
and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance
with accounting principles generally accepted in the United States. The preparation of our financial statements requires us to make estimates
and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at
the date of our financial statements, as well as the reported revenues and expenses during the reported periods. We evaluate these estimates
and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable
under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that
are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

In-Process Research and Development

The Company evaluates the
carrying value of indefinite-lived intangible assets, which consists of in-process research and development (“IPR&D”),
on an annual basis